Evidence map›Paper›PMID 30285657›Full record

ReviewBMC cancer2018

Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options.

Maxi Wass, Marcus Bauer, Roald Pfannes, Kerstin Lorenz, Andreas Odparlik, Lutz P Müller, Claudia Wickenhauser

Abstract readCase ReportsReview
In one paragraph

Review in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. A rare B-cell type chronic active Epstein-Barr virus infection patient mimicking lymphoma onAmerican journal of nuclear medicine and molecular imaging · 2022
    Article
  4. Review
  5. Article
  6. Article
  7. Novel Therapeutics for Epstein⁻Barr Virus.Molecules (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maxi WassDepartment of Hematology and Oncology, University Hospital Halle, Germany, Ernst-Grube-Str. 40, Halle, 06120, Germany. maxi.wass@uk-halle.de.ORCID http://orcid.org/0000-0002-5380-1608
Marcus BauerDepartment of Pathology, University Hospital Halle, Germany, Magdeburger Str. 2, Halle, 06112, Germany. marcus.bauer@uk-halle.de.
Roald PfannesDepartment of Hematology and Oncology, University Hospital Halle, Germany, Ernst-Grube-Str. 40, Halle, 06120, Germany.
Kerstin LorenzDepartment of General Visceral, Vascular and Endocrine Surgery, University Hospital Halle, Germany, Ernst-Grube-Str. 40, Halle, 06120, Germany.
Andreas OdparlikDepartment of Radiation Therapy and Nuclear Medicine, University Hospital Halle, Germany, Ernst-Grube-Str. 40, Halle, 06120, Germany.
Lutz P MüllerDepartment of Hematology and Oncology, University Hospital Halle, Germany, Ernst-Grube-Str. 40, Halle, 06120, Germany.
Claudia WickenhauserDepartment of Pathology, University Hospital Halle, Germany, Magdeburger Str. 2, Halle, 06112, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic active Epstein-Barr virus (EBV) infection (CAEBV) of the T-/NK-cell type, systemic form is a rare and potentially life-threatening illness caused by persistent EBV infection. The highest incidence is found in children and adolescents with increased frequency among Asians and Native Americans, while the disease is uncommon in Western countries. Typically patients present with unspecific symptoms, like fever, lymphadenopathy, hepatosplenomegaly and liver dysfunction. Due to fatal complications including hemophagocytic syndrome, coagulopathy, multiple organ failure and development of EBV-positive lymphoproliferative disease (LPD) or lymphoma early diagnosis is critical for successful treatment. However, in consequence of the lack of experience due to the low incidence in Europe, a broad spectrum of clinical manifestations and a particularly unexpected group of patients, diagnosis can be challenging. Inhere we describe the clinicopathological findings of an African adult with CAEBV associated LPD with a brief review of the literature. CASE PRESENTATION: A 42-year-old African man with fever, enlargement of the spleen and a suspected epileptic seizure was referred to our hospital. Diagnostic testing repeatedly revealed a massive EBV-DNA load in peripheral blood. Whole-body PET-CT-scan presented a strong uptake at multiple bone marrow sites, the thyroid and the adrenal glands. Histopathological analysis of bone marrow and thyroid gland revealed a highly proliferating, atypical and predominantly intravascular cytotoxic T-cell population with intracellular EBV-encoded RNA. Clonality analysis revealed the presence of polyclonal T-cell-receptor. Based on these findings a CAEBV of the T-/NK-cell type, systemic form was diagnosed. Subsequent therapy including three cycles of chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisolone resulted in decreased EBV load, clinical improvement and ongoing complete remission.

conclusionAdult-onset CAEBV of T/NK-cell type usually comprises a poor prognosis and is extremely rare in Western countries. Therefore, our case highlights the need for a clinical awareness of this disease in patients with systemic illness and for a comprehensive multidisciplinary diagnostic approach to facilitate diagnosis. Treatment options include antiviral drugs, immunosuppressive agents and systemic chemotherapy with or without allogeneic stem cell transplantation. Given the limited data these options need to be decided upon in each patient individually considering severity of the disease, comorbidities and response.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBiopsyBlack PeopleChronic DiseaseCyclophosphamideDoxorubicinEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansImmunophenotypingLymph NodesMalePositron Emission Tomography Computed TomographyPrednisoneBiomarkersCyclophosphamideDoxorubicinPrednisoneVincristineAdultsChronic active Epstein-Barr virus infectionDiagnostic standardsEpstein-Barr virusT/NK-cell lymphoproliferative diseaseTreatmentWestern countries

Identifiers

PMID30285657
PMCPMC6169008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.